Epcoritamab monotherapy [EPC2]

Epcoritamab monotherapy for previously treated adult patients with relapsed/refractory follicular lymphoma who have received 2 or more lines of systemic therapy where the following criteria have been met:

1. This application is being made by, and the first cycle of systemic anti-cancer therapy with epcoritamab monotherapy will be prescribed by, a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
2. The patient has a histologically confirmed diagnosis of follicular lymphoma that has either relapsed following, or is refractory to, 2 or more lines of standard routinely commissioned systemic therapies.
3. Below are the number of lines of systemic therapy that the patient has received for the treatment of follicular lymphoma.

Note

Note: patients who have had only 1 line of systemic therapy are not eligible for treatment with epcoritamab. Please record the number of lines of previous systemic therapy below: 2 previous lines OR 3 previous lines OR 4 or more previous lines

4. The patient has not been previously treated with epcoritamab unless epcoritamab monotherapy needs to be continued following an Abbvie compassionate access scheme and all other treatment criteria on this form are fulfilled. Please record in the box below which of the following applies to this patient:

• no previous treatment with epcoritamab OR
• continuation of previous treatment with epcoritamab monotherapy via an Abbvie compassionate access scheme and all other criteria on this form are fulfilled

5. The patient has not received any previous treatment with a bispecific antibody targeting both CD20 and CD3 other than epcoritamab as specified above in criterion 4.
6. The patient has an ECOG performance status score of 0 or 1 or 2.
7. Epcoritamab is to be administered as monotherapy and not in combination with any other systemic therapies for lymphoma.
8. Treatment with epcoritamab monotherapy will be stopped at whichever of the following events occurs first: disease progression, unacceptable toxicity or maximum 3 years of treatment regardless of response status at that time. Once epcoritamab is electively stopped (ie not for reasons of toxicity), it cannot be re-started.
9. When a treatment break of more than 6 weeks beyond the expected 4-weekly cycle length is needed, a treatment break approval form will be completed to restart treatment.
10. Epcoritamab will otherwise be used as set out in its Summary of Product Characteristics.

CDF funded From: 23 February 2026

Additional information

Form version: -

CDF Managed Access: No

NICE Technology Appraisal: NA (NA)

Current Form Version

Important

This is an older version of the form. To view the most up to date form follow this link

Older Form Versions

There are previous versions of this form. These may not all be available on this site.